

# Alexander C Fanaroff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6731187/publications.pdf>

Version: 2024-02-01

79  
papers

1,608  
citations

331538

21  
h-index

315616

38  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Seeking patient-centered trial outcomes: The case for days alive out of hospital. <i>American Heart Journal</i> , 2022, 248, 172-174.	1.2	3
2	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. <i>JAMA Cardiology</i> , 2022, 7, 150.	3.0	37
3	Economic Considerations in Access to Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011489.	1.4	8
4	Rural-Urban Disparities in Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2022, 79, 280-282.	1.2	4
5	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
6	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. <i>European Heart Journal Supplements</i> , 2022, 24, A19-A31.	0.0	6
7	Epidemiology and Outcomes of Patients Readmitted to the Intensive Care Unit After Cardiac Intensive Care Unit Admission. <i>American Journal of Cardiology</i> , 2022, 170, 138-146.	0.7	0
8	Independence of clinical events committees: A consensus statement from clinical research organizations. <i>American Heart Journal</i> , 2022, 248, 120-129.	1.2	2
9	Recognising acute coronary syndrome. <i>BMJ, The</i> , 2022, 377, e069591.	3.0	5
10	Percutaneous Coronary Intervention in Acute Coronary Syndrome and Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 887-889.	1.1	2
11	Association between intensive care unit utilization for patients with non-“ST-segment elevation myocardial infarction and patient experience. <i>American Heart Journal</i> , 2021, 231, 32-35.	1.2	0
12	Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. <i>European Journal of Internal Medicine</i> , 2021, 83, 8-9.	1.0	0
13	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. <i>American Heart Journal</i> , 2021, 232, 1-9.	1.2	6
14	Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010331.	1.4	0
15	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non-“ST-Segment“Elevation Myocardial Infarction for Intensive Care Unit Admission. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007602.	0.9	4
16	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. <i>JAMA Network Open</i> , 2021, 4, e216139.	2.8	187
17	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. <i>Circulation: Heart Failure</i> , 2021, 14, e008277.	1.6	1
18	Adding Precision to Defining Bleeding and Ischemic Risk With PCI in Cancer Patients. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1106-1108.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Reporting of Percutaneous Coronary Interventions Site-Specific Mortality—Reply. <i>JAMA Cardiology</i> , 2021, 6, 1344.	3.0	0
20	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010750.	1.4	0
21	Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. <i>Journal of the American Heart Association</i> , 2021, 10, e021456.	1.6	42
22	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012–2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008260.	0.9	27
23	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2344-2349.	1.1	11
24	Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2213-2217.	1.2	1
25	1 Month of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2073-2075.	1.2	0
26	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. <i>JAMA Health Forum</i> , 2021, 2, e214182.	1.0	58
27	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Progress in Cardiovascular Diseases</i> , 2021, 69, 11-17.	1.6	1
28	Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011232.	1.4	9
29	Radial Access for Peripheral Interventions. <i>Interventional Cardiology Clinics</i> , 2020, 9, 53-61.	0.2	5
30	Anticoagulation in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1827-1829.	1.2	10
31	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
32	Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. <i>European Heart Journal</i> , 2020, 41, 4505-4507.	1.0	3
33	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009179.	1.4	9
34	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006182.	0.9	5
35	Association Between Intensive Care Unit Usage and Long-Term Medication Adherence, Mortality, and Readmission Among Initially Stable Patients With Non-ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e015179.	1.6	4
36	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. <i>JAMA Cardiology</i> , 2020, 5, 532.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes and need for intensive care after non-ST-segment-elevation myocardial infarction. <i>European Journal of Internal Medicine</i> , 2020, 76, 58-63.	1.0	8
38	Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008227.	1.4	49
39	Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. <i>Trials</i> , 2020, 21, 323.	0.7	3
40	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020, 226, 4-12.	1.2	6
41	New Approaches to Conducting Randomized Controlled Trials. <i>Journal of the American College of Cardiology</i> , 2020, 75, 556-559.	1.2	17
42	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009975.	1.4	1
43	Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry. <i>American Heart Journal</i> , 2019, 215, 167-177.	1.2	17
44	High-quality evidence to inform clinical practice. <i>Lancet, The</i> , 2019, 394, 633-634.	6.3	10
45	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2019, 214, 184-193.	1.2	8
46	Physiologic Assessment of Stent Deployment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007955.	1.4	0
47	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
48	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) <i>Tj ETQq0 0 0 0 BT /Overclock 10 Tf</i>	1.0	0
49	Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. <i>American Journal of Cardiology</i> , 2019, 123, 1399-1405.	0.7	5
50	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 458-472.	1.6	43
51	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
52	Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. <i>Annual Review of Medicine</i> , 2019, 70, 61-75.	5.0	9
53	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor) <i>Tj ETQq1 1 0.7843 14 rgBT /Ov</i>	1.6	2
54	Stroke prevention in atrial fibrillation: re-defining "real-world data"™ within the broader data universe. <i>European Heart Journal</i> , 2018, 39, 2932-2941.	1.0	22

#	ARTICLE	IF	CITATIONS
55	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004675.	0.9	20
56	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	0.9	51
57	A Path Forward for Regenerative Medicine. <i>Circulation Research</i> , 2018, 123, 495-505.	2.0	6
58	Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1837-1847.	1.1	29
59	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non-â€œST-Segmentâ€œ Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	26
60	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2304-2313.	1.2	14
61	Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2913-2924.	1.2	104
62	PATTERNS OF ANGINA AND ANTIANGINAL MEDICATION USE AMONG PATIENTS FOLLOWING MI TREATED WITH PCI: INSIGHTS FROM TRANSLATE-ACS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1.	1.2	0
63	ANTIPLATELET THERAPY CHANGES FOR MI PATIENTS WITH RECURRENT ISCHEMIC EVENTS: INSIGHTS INTO CONTEMPORARY PRACTICE FROM THE TRANSLATE-ACS STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 24.	1.2	1
64	PERIPHERAL ARTERY DISEASE AND TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A REPORT FROM THE STS/TVT REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 991.	1.2	1
65	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017, 241, 87-96.	0.8	24
66	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	79
67	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	23
68	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
69	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-â€œST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 36.	3.0	31
70	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	1.4	12
71	Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2016, 5, 221-237.	0.2	5
72	Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a High-Risk Population. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	1

#	ARTICLE	IF	CITATIONS
73	Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2015, 314, 1990.	3.8	9
74	Conundrums for Atrial Fibrillation Management in Older Adults. Current Geriatrics Reports, 2015, 4, 368-376.	1.1	0
75	Does This Patient With Chest Pain Have Acute Coronary Syndrome?. JAMA - Journal of the American Medical Association, 2015, 314, 1955.	3.8	170
76	Patient Selection for Advanced Heart Failure Therapy Referral. Critical Pathways in Cardiology, 2014, 13, 1-5.	0.2	17
77	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	1.2	4
78	Kalirin Promotes Neointimal Hyperplasia by Activating Rac in Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 702-708.	1.1	40
79	G Protein-Coupled Receptor Kinase-5 Attenuates Atherosclerosis by Regulating Receptor Tyrosine Kinases and 7-Transmembrane Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 308-316.	1.1	38